News for NeoGenomics, Inc. (NEO)

Bank of America has revised its price target for NeoGenomics (NEO), reducing it from $16 to $12 while maintaining a Neutral rating on the stock. The adjustment

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, to

NeoGenomics (NEO) said that Tony Zook has officially assumed the role of CEO, a member of the company’s Board of Directors since 2023.

Summary NeoGenomics Inc (NEO), a leading provider of oncology diagnostic solutions, announced the promotion of Warren Stone to President & Chief Operating Offic

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pa

NeoGenomics is rated a Hold despite its growth potential. Analyze intrinsic value, profitability concerns, and the reasons for the decline in the share price. See more.

NeoGenomics Inc (NEO), a prominent oncology testing services company, has announced its participation in several upcoming investor conferences. The company will

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will particip

Operator: Welcome to the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

NeoGenomics Inc (NEO), a leading oncology testing services company, announced its financial results for the fourth quarter and full year ending December 31, 202

Revenue: $172 million for Q4, marking the ninth consecutive quarter of double-digit growth.Clinical Testing Volumes: Increased by 9% year-over-year.Revenue per

NeoGenomics (NEO) shares experienced a significant drop of 24.13% following the release of its earnings report, which revealed that the company's revenue failed

The following slide deck was published by NeoGenomics, Inc.

NeoGenomics (NEO) posts strong Q4 2024 results with $172M revenue, 24% NGS growth, and ambitious 2025 goals.

NeoGenomics (NEO) delivered earnings and revenue surprises of 100% and 0.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics, Inc. (Nasdaq: NEO) (the ”œCompany”), a leading oncology testing services company, today announced its fourth-quarter and full year results for

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) made a strategic decision to reduce its holdings in NeoGenomics Inc (NEO) by 438,117 shares.

Shares of NeoGenomics Inc (NEO) surged 4.60% in mid-day trading on Feb 14. The stock reached an intraday high of $14.73, before settling at $14.55, up from

NeoGenomics (NEO) to release Q4 earnings on Feb 18. Can it maintain its streak of beating revenue & EPS estimates? Consensus EPS: $0.03, Revenue: $173.4M.